Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Dartmouth researchers have developed a protocol that permits cells harvested from melanoma tumors in mice to grow readily in cell culture. Their findings were published in an article, Multiple murine BRafV600E melanoma cell lines with sensitivity to PLX4032, in the journal Pigment Cell & Melanoma Research.
"We anticipate that these cell lines will be extremely useful to many investigators who use mouse melanoma as a model system," said Constance E. Brinckerhoff, PhD, professor of Medicine and of Biochemistry at the Geisel School of Medicine at Dartmouth and a member of the Norris Cotton Cancer Center (NCCC) Mechanism Research Program.
There is a lack of mouse cell lines that harbor the BRAF mutation that is so prevalent in human melanomas, and the cell lines that are available grow slowly in culture and are not representative of human melanoma cell lines. Detailed experiments on molecular mechanisms controlling mouse cell line behavior have been difficult because the currently available mouse cell lines do not grow well in culture.
The Geisel School of Medicine researchers are the first to have developed a protocol that permits mouse melanoma cells to be harvested from tumors in the mice and to grow readily in cell culture. Importantly, these cell lines are genetically compatible with a strain of mice that are immunologically competent, while human cells need to be placed into immunologically weakened mice in order to grow. Thus, the ability to study these mouse melanoma cell lines both in culture and in mice with an intact immune system is an experimental advantage.
This research was funded, in part, by: NIH P30 - Center for Molecular, Cellular and Translational Research (Cancer Center Training Grant CA009658 (MHJ/CEB); NIH T32 – Immunology Training Grant AI007363 (MHJ/DWM); NIH T32 – Molecular and Cellular Biology Training Grant GM00874 (SMS/MJT); NIH R01 AR-26599 and CA-77267 (CEB); NIH R01 CA120777 (MJT); The American Cancer Society RSG LIB-121864 (MJT); the Melanoma Research Alliance Development Award (MJT); Hitchcock Foundation Pilot Studies Award (DWM and CEB); and NIH R01 CA134799 (DWM).
Multiple murine BRafV600E melanoma cell lines with sensitivity to PLX4032. Pigment Cell Melanoma Res. 2014 Jan 25. doi: 10.1111/pcmr.12220
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Melanoma / Skin Cancer category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
The Geisel School of Medicine at Dartmouth. "Protocol developed to harvest mouse cell lines for melanoma research." Medical News Today. MediLexicon, Intl., 4 Feb. 2014. Web.
8 Mar. 2014. <http://www.medicalnewstoday.com/releases/272072>
The Geisel School of Medicine at Dartmouth. (2014, February 4). "Protocol developed to harvest mouse cell lines for melanoma research." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/272072.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.